Clinical Trial Finder

Inclusion Criteria:

• - 18 years of age or older.

• - Histologically confirmed diagnosis of melanoma or malignant brain tumor at MSKCC.

• - Newly-diagnosed or recurrent (local,regional, metastatic) metastatic melanoma or malignant brain tumor patients with.

• - Residual clinically or radiographically evident tumor, including primary cutaneous and mucosal melanomas or malignant brain tumor.

• - Prior radiation therapy, chemotherapy, or surgery in patients requiring flap reconstruction in the head and neck region.

• - Newly diagnosed patients with previous excisional biopsy.

• - Normal baseline cardiac function based upon pre-operative evaluation.

• - At the discretion of the physician ANC>1000/mcl and platelets>100,000/mcl.

• - At the discretion of the physician Bilirubin level of < 2.0 mg/dl in the absence of a history of Gilbert's disease (or pattern consistent with Gilbert's).

• - If patients have a history of malignancy other than melanoma or malignant brain tumor they must be disease-free (excluding primary cancer for metastatic patients) for ≥ 5 years at the time of enrollment.

• - All patients of childbearing and child-creating age must be using an acceptable form of birth control.

• - Women who are pre-menopausal must have a negative serum pregnancy test.

Exclusion Criteria:

• - Abnormal thyroid function, such as untreated clinical diagnosis of hypothyroidism, hyperthyroidism, or other thyroid disease.

• - Known pregnancy or breast-feeding.

• - Medical illness unrelated to the tumor which in the opinion of the attending physician and principal investigator will preclude administration of the tracer.

This includes patients with uncontrolled infection, chronic renal insufficiency, myocardial infarction within the past 6 months, unstable angina, cardiac arrhythmias other than chronic atrial fibrillation and chronic active or persistent hepatitis, or New York Heart Association Classification III or IV heart disease.

• - History of any malignancy (excluding primary cancer for metastatic patients) other than melanoma or malignant brain tumors for which the disease-free interval is <5 years.

• - Allergic reaction to iodine-containing contrast material.

• - Weight greater than the 400-lb weight limit of the PET scanner.

• - Claustrophobia.

- Inability to lie in the scanner for 30 minutes

Arms

Experimental: newly diagnosed or recurrent head/neck melanoma

This is a two-year microdosing study that will enroll 5 metastatic melanoma patients and 18 malignant brain tumor patients (surgical (n=13) and non-surgical candidates (n=5)). We have already accrued 5 melanoma patients and expect to accrue brain tumor patients within a 1 year period.

Interventions

Drug: - PET scan with 124I-cRGDY-PEG-dots

Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.